Special Session 20
3月27日［土］09:45-11:15
|
| |
| |
Future potential as a drug of natriuretic peptides
|
|
|
| |
| |
|
|
| |
ナトリウム利尿ペプチド関連薬剤としてはカルペリチドとARNIがあるが、さらに新しい薬剤も考案されている。この分野の発展は心不全治療の向上と病態生理の解明に繋がると期待されており、議論を深めたい。
|
|
|
| |
| |
|
|
| |
| |
 |
|
Michihiro Yoshimura
Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
|
|
 |
|
John C Burnett Jr
Cardiovascular Medicine Mayo Clinic, Mayo Clinic, Rochester, USA
|
|
|
| |
| |
|
|
| |
| |
|
|
John C Burnett Jr
Cardiovascular Medicine Mayo Clinic, Mayo Clinic, Rochester, USA
|
|
 |
|
Elijah Bolotin
PharmaIN Corporation CEO, PharmaIN Corporation, Bothell, USA
|
|
|
| |
| |
 |
|
Hitoshi Nakagawa
Department of Cardiovascular Medicine, Nara Medical University, Kashihara
|
|
 |
|
Yasuaki Nakagawa
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto
|
|
|
| |
| |
 |
|
Tomohisa Nagoshi
Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
|
|
|
|
|
|
| |
| |
|
|